Atsushi Fushimi

974 total citations
39 papers, 510 citations indexed

About

Atsushi Fushimi is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Atsushi Fushimi has authored 39 papers receiving a total of 510 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 14 papers in Molecular Biology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Atsushi Fushimi's work include RNA modifications and cancer (8 papers), Breast Cancer Treatment Studies (5 papers) and Glycosylation and Glycoproteins Research (4 papers). Atsushi Fushimi is often cited by papers focused on RNA modifications and cancer (8 papers), Breast Cancer Treatment Studies (5 papers) and Glycosylation and Glycoproteins Research (4 papers). Atsushi Fushimi collaborates with scholars based in Japan, United States and China. Atsushi Fushimi's co-authors include Nami Yamashita, Donald Küfe, Masayuki Hagiwara, Mark D. Long, Atrayee Bhattacharya, Song Liu, Mototsugu Oya, Yota Yasumizu, Hasan Rajabi and Tsuyoshi Hata and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Atsushi Fushimi

34 papers receiving 509 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Atsushi Fushimi Japan 13 329 201 123 109 84 39 510
Hyo‐Gyoung Kang South Korea 14 342 1.0× 182 0.9× 150 1.2× 135 1.2× 47 0.6× 34 561
Roi Villar-Vázquez Spain 6 263 0.8× 175 0.9× 99 0.8× 63 0.6× 86 1.0× 6 466
Hanlin Mok United States 5 292 0.9× 187 0.9× 70 0.6× 103 0.9× 90 1.1× 7 462
Katheryn Begg United Kingdom 4 281 0.9× 163 0.8× 164 1.3× 82 0.8× 60 0.7× 7 505
Hao Mo China 13 226 0.7× 135 0.7× 85 0.7× 86 0.8× 54 0.6× 32 436
Liwei Song China 13 319 1.0× 125 0.6× 140 1.1× 97 0.9× 76 0.9× 21 502
Saori Tomita Japan 10 210 0.6× 137 0.7× 123 1.0× 164 1.5× 109 1.3× 12 552
Tatiana S. Gerashchenko Russia 12 188 0.6× 226 1.1× 160 1.3× 92 0.8× 125 1.5× 37 502
Reyno Del Rosario United States 10 325 1.0× 171 0.9× 127 1.0× 76 0.7× 29 0.3× 11 476
Jun Deng China 13 230 0.7× 178 0.9× 82 0.7× 83 0.8× 122 1.5× 30 460

Countries citing papers authored by Atsushi Fushimi

Since Specialization
Citations

This map shows the geographic impact of Atsushi Fushimi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Atsushi Fushimi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Atsushi Fushimi more than expected).

Fields of papers citing papers by Atsushi Fushimi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Atsushi Fushimi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Atsushi Fushimi. The network helps show where Atsushi Fushimi may publish in the future.

Co-authorship network of co-authors of Atsushi Fushimi

This figure shows the co-authorship network connecting the top 25 collaborators of Atsushi Fushimi. A scholar is included among the top collaborators of Atsushi Fushimi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Atsushi Fushimi. Atsushi Fushimi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shigeta, Keisuke, Hiroshi Hongo, Sheng‐Yu Ku, et al.. (2025). MUC1-C dependence in treatment-resistant prostate cancer uncovers a target for antibody-drug conjugate therapy. JCI Insight. 10(14). 1 indexed citations
2.
Yoshida, Atsushi, Naoki Hayashi, Yukinori Ozaki, et al.. (2025). Risk factors for early recurrence in patients with hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study in Japan (WJOG15721B). Breast Cancer. 32(4). 757–772. 1 indexed citations
3.
Katori, Hideaki, et al.. (2024). Development and evaluation of 3D-printed tumor palpation models for surgical training and patient education. SHILAP Revista de lepidopterología. 10(1). 41–41.
4.
Haratake, Naoki, Atrayee Bhattacharya, Weipu Mao, et al.. (2024). IDENTIFICATION OF MUC1-C AS A TARGET FOR SUPPRESSING PROGRESSION OF HEAD AND NECK SQUAMOUS CELL CARCINOMAS. Cancer Research Communications. 4(5). 1268–1281. 4 indexed citations
5.
Bhattacharya, Atrayee, Chi Ngai Chan, Atsushi Fushimi, et al.. (2024). MUC1-C regulates NEAT1 lncRNA expression and paraspeckle formation in cancer progression. Oncogene. 43(28). 2199–2214. 9 indexed citations
6.
Bhattacharya, Atrayee, Atsushi Fushimi, Keyi Wang, et al.. (2023). MUC1-C intersects chronic inflammation with epigenetic reprogramming by regulating the set1a compass complex in cancer progression. Communications Biology. 6(1). 1030–1030. 13 indexed citations
7.
Morimoto, Yoshihiro, Nami Yamashita, Naoki Haratake, et al.. (2023). MUC1-C is a master regulator of MICA/B NKG2D ligand and exosome secretion in human cancer cells. Journal for ImmunoTherapy of Cancer. 11(2). e006238–e006238. 16 indexed citations
8.
Fushimi, Atsushi, Yoshihiro Morimoto, Satoshi Ishikawa, et al.. (2022). Dependence on the MUC1-C Oncoprotein in Classic, Variant, and Non–neuroendocrine Small Cell Lung Cancer. Molecular Cancer Research. 20(9). 1379–1390. 12 indexed citations
9.
Yamashita, Nami, Yoshihiro Morimoto, Atsushi Fushimi, et al.. (2022). MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer. Molecular Cancer Research. 21(3). 274–289. 25 indexed citations
10.
Morimoto, Yoshihiro, Atsushi Fushimi, Nami Yamashita, et al.. (2022). Addiction of Merkel cell carcinoma to MUC1-C identifies a potential new target for treatment. Oncogene. 41(27). 3511–3523. 16 indexed citations
11.
Fushimi, Atsushi, et al.. (2022). Raising Breast Awareness via YouTube. Nihon Nyugan Kenshin Gakkaishi (Journal of Japan Association of Breast Cancer Screening). 31(1). 31–37.
12.
Morimoto, Yoshihiro, Atsushi Fushimi, Nami Yamashita, et al.. (2021). MUC1-C dictates neuroendocrine lineage specification in pancreatic ductal adenocarcinomas. Carcinogenesis. 43(1). 67–76. 14 indexed citations
13.
Hagiwara, Masayuki, Yota Yasumizu, Nami Yamashita, et al.. (2020). MUC1-C Activates the BAF (mSWI/SNF) Complex in Prostate Cancer Stem Cells. Cancer Research. 81(4). 1111–1122. 62 indexed citations
14.
Tabei, Isao, et al.. (2020). Male breast metastasis of ureteral cancer: a case report. SHILAP Revista de lepidopterología. 6(1). 58–58. 3 indexed citations
15.
Li, Wei, Ning Zhang, Caining Jin, et al.. (2020). MUC1-C drives stemness in progression of colitis to colorectal cancer. JCI Insight. 5(12). 47 indexed citations
16.
Fushimi, Atsushi, et al.. (2020). High-Dose Toremifene as a Promising Candidate Therapy for Hormone Receptor-Positive Metastatic Breast Cancer with Secondary Resistance to Aromatase Inhibitors. International Journal of Breast Cancer. 2020. 1–7. 3 indexed citations
17.
Hata, Tsuyoshi, Hasan Rajabi, Hidekazu Takahashi, et al.. (2019). MUC1-C Activates the NuRD Complex to Drive Dedifferentiation of Triple-Negative Breast Cancer Cells. Cancer Research. 79(22). 5711–5722. 47 indexed citations
18.
Fushimi, Atsushi, et al.. (2019). Do Decreased Breast Microcalcifications After Neoadjuvant Chemotherapy Predict Pathologic Complete Response?. Clinical Breast Cancer. 20(1). e82–e88. 8 indexed citations
19.
Mimoto, Rei, Satomi Yogosawa, Atsushi Fushimi, et al.. (2019). Clinical implications of drug-screening assay for recurrent metastatic hormone receptor-positive, human epidermal receptor 2-negative breast cancer using conditionally reprogrammed cells. Scientific Reports. 9(1). 13405–13405. 6 indexed citations
20.
Fushimi, Atsushi, Hiroshi Takeyama, & Yoshinobu Manome. (2018). Effect of Heparin–Protamine Treatment on Thyroid Cancer Cell Lines. Anticancer Research. 38(12). 6759–6762. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hyo‐Gyoung Kang Breakdown of academic impact, for papers by Roi Villar-Vázquez Breakdown of academic impact, for papers by Hanlin Mok Breakdown of academic impact, for papers by Katheryn Begg Breakdown of academic impact, for papers by Hao Mo Breakdown of academic impact, for papers by Liwei Song Breakdown of academic impact, for papers by Saori Tomita Breakdown of academic impact, for papers by Tatiana S. Gerashchenko Breakdown of academic impact, for papers by Reyno Del Rosario Breakdown of academic impact, for papers by Jun Deng
Rankless by CCL
2026